SR49059

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H317：アレルギー性皮膚反応を起こすおそれ

• 注意書き

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

SR49059 価格

SR49059 化学特性,用途語,生産方法

• 使用

  Relcovaptan is a selective vasopressin-1a receptor antagonist that prevents cellular swelling and provides treatment for post-traumatic brain edema.

• 生物活性

  Potent and selective non-peptide vasopressin V 1A receptor antagonist; devoid of agonist activity. Displays high affinity and efficacy at both rat (K i = 1.6 nM) and human (K i = 1.1-6.3 nM) V 1A receptors. Potently antagonizes arginine vasopressin-induced effects in vitro (IC 50 = 3.7 nM for inhibition of human platelet aggregation) and is orally active in vivo .

• Biochem/physiol Actions

  SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist. AVP is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes V1a, V1b, and V2. All belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF. SR 49059 has also shown initial positive results in the treatment of Raynaud′s disease, dysmenorrhoea, and tocolysis.

SR49059 生産企業

Global(53)Suppliers

150375-75-0, SR49059 キーワード